#Zentiva #Biopharmaceutical #Czech Republic #Prague #Biosimilar

Zentiva Expands Its Biopharmaceutical Portfolio

Pharmaceutical company Zentiva has made a significant breakthrough by entering the EU biosimilar market with its first monoclonal antibody biosimilar. This important step was announced on December 1, 2025, following approval from the European Medicines Agency (EMA). The launch not only strengthens Zentiva's position as a reliable healthcare partner but is also a vital move towards enhancing patient access to high-quality biological treatments across Europe.

Strategic Significance of the Launch

Steffen Saltofte, CEO of Zentiva, highlighted the importance of this launch, stating, “Today’s launch is a key milestone for Zentiva. We are making a significant advance in the realm of biological medicine. Biosimilars are a natural extension of our mission to make high-quality treatments more accessible and affordable to people across Europe.” The introduction of this biosimilar not only presents a new treatment option for patients but also positions Zentiva for sustainable growth within one of the fastest-growing segments of the pharmaceutical industry.

What is the New Biosimilar?

The newly launched biosimilar is a monoclonal antibody that treats bone-related diseases. It has undergone stringent evaluations under the EMA's centralized procedure and will gradually become available in various European markets starting this December. With this introduction, Zentiva aims to diversify its product range beyond traditional generics in response to the increasing demand for biologics in healthcare.

Importance of Biosimilars in Healthcare

As healthcare costs continue to rise, the development of biosimilars is crucial for sustainable healthcare systems. By offering cost-effective alternatives to expensive biological medications, biosimilars can play a pivotal role in improving access to modern treatment options for patients. With its first biosimilar product, Zentiva engages effectively with ongoing trends in the pharmaceutical market, emphasizing its commitment to delivering value for patients and healthcare providers.

Zentiva’s Commitment to Quality and Accessibility

Zentiva has been at the forefront of health and well-being for generations, focusing on developing, manufacturing, and supplying high-quality, accessible medications to over 100 million people in more than 30 countries in Europe and beyond. The company's operations include four manufacturing facilities and a robust network of third-party manufacturing partners, ensuring supply chain reliability.

With a dedicated workforce of over 5,000 employees, Zentiva is united by a common goal: to make medicines accessible to those who need them daily. This commitment is reflected in their ambitious development plan aimed at expanding their product offerings in the coming years.

For more information about Zentiva and their newly launched biosimilar, visit www.zentiva.com.